Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 3078

Sort by

Sort Order Select

Journal Articles

CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel

Blood (2021) 138 (12): 1081–1085.

https://doi.org/10.1182/blood.2021010930

Published: 2021

Includes: Supplemental data

Journal Articles

Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy

Kitsada Wudhikarn, Jessica R. Flynn, Isabelle Rivière, Mithat Gönen, Xiuyan Wang, Brigitte Senechal, Kevin J. Curran, Mikhail Roshal, Peter G. Maslak, Mark B. Geyer, Elizabeth F. Halton, Claudia Diamonte, Marco L. Davila, Michel Sadelain, Renier J. Brentjens, Jae H. Park

Blood (2021) 138 (7): 531–543.

https://doi.org/10.1182/blood.2020009515

Published: 2021

Includes: Supplemental data

Journal Articles

Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma

Jonathan A. Trujillo, James Godfrey, Yifei Hu, Jun Huang, Sonali M. Smith, Matthew J. Frigault, Zachariah DeFilipp, Daniel Appelbaum, Yonglin Pu, Nicholas Feinberg, Thomas Althaus, Michael R. Bishop, Peter A. Riedell, Justin Kline

Blood (2021) 137 (24): 3454–3459.

https://doi.org/10.1182/blood.2020009148

Published: 2021

Journal Articles

Utility of a safety switch to abrogate CD19.CAR T-cell–associated neurotoxicity

Matthew C. Foster, Barbara Savoldo, Winnie Lau, Clio Rubinos, Natalie Grover, Paul Armistead, James Coghill, Robert S. Hagan, Kaitlin Morrison, Faith Brianne Buchanan, Catherine Cheng, Spencer Laing, Anastasia Ivanova, John West, Aaron Foster, Jonathan Serody, Gianpietro Dotti

Blood (2021) 137 (23): 3306–3309.

https://doi.org/10.1182/blood.2021010784

Published: 2021

Includes: Supplemental data

Journal Articles

Notch signaling promotes disease initiation and progression in murine chronic lymphocytic leukemia

Delphine Tardivon, Mateusz Antoszewski, Nadine Zangger, Marianne Nkosi, Jessica Sordet-Dessimoz, Rudi Hendriks, Ute Koch, Freddy Radtke

Blood (2021) 137 (22): 3079–3092.

https://doi.org/10.1182/blood.2020006701

Published: 2021

Includes: Supplemental data

Journal Articles

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay M. Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl

Blood (2021) 137 (19): 2634–2645.

https://doi.org/10.1182/blood.2020007512

Published: 2021

Includes: Supplemental data

Journal Articles

CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma

Blood (2021) 137 (17): 2321–2325.

https://doi.org/10.1182/blood.2020009432

Published: 2021

Includes: Supplemental data

Journal Articles

Cryptic insertion of KMT2A , a rare t(9;11) variant

Nada Assaf, Christine Terré

Blood (2021) 137 (13): 1843.

https://doi.org/10.1182/blood.2020010442

Published: 2021

Journal Articles

DARTs point the way forward in AML

Saar Gill

Blood (2021) 137 (6): 720–721.

https://doi.org/10.1182/blood.2020009020

Published: 2021

Journal Articles

Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR

Dana Stenger, Tanja A. Stief, Theresa Kaeuferle, Semjon Willier, Felicitas Rataj, Kilian Schober, Binje Vick, Ramin Lotfi, Beate Wagner, Thomas G. P. Grünewald, Sebastian Kobold, Dirk H. Busch, Irmela Jeremias, Franziska Blaeschke, Tobias Feuchtinger

Blood (2020) 136 (12): 1407–1418.

https://doi.org/10.1182/blood.2020005185

Published: 2020

Includes: Supplemental data

Journal Articles

Curran KJ, Margossian SP, Kernan NA, et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood. 2019;134(26):2361-2368.

Blood (2020) 136 (11): 1374.

https://doi.org/10.1182/blood.2020008394

Published: 2020

Journal Articles

How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies

Joshua A. Hill, Susan K. Seo

Blood (2020) 136 (8): 925–935.

https://doi.org/10.1182/blood.2019004000

Published: 2020

Includes: Supplemental data

Journal Articles

Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure

Jordan Gauthier, Alexandre V. Hirayama, Janaki Purushe, Kevin A. Hay, James Lymp, Daniel H. Li, Cecilia C. S. Yeung, Alyssa Sheih, Barbara S. Pender, Reed M. Hawkins, Aesha Vakil, Tinh-Doan Phi, Rachel N. Steinmetz, Mazyar Shadman, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle

Blood (2020) 135 (19): 1650–1660.

https://doi.org/10.1182/blood.2019002936

Published: 2020

Includes: Supplemental data

Journal Articles

Long-term outcomes of Sleeping Beauty–generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas

Blood (2020) 135 (11): 862–865.

https://doi.org/10.1182/blood.2019002920

Published: 2020

Journal Articles

How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy

Ibrahim Aldoss, Stephen J. Forman

Blood (2020) 135 (11): 804–813.

https://doi.org/10.1182/blood.2019002132

Published: 2020

Journal Articles

Supercharging your CAR

Sneha Ramakrishna, Kara L. Davis

Blood (2020) 135 (9): 593–594.

https://doi.org/10.1182/blood.2019004469

Published: 2020

Journal Articles

Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity

Olli Dufva, Jan Koski, Pilvi Maliniemi, Aleksandr Ianevski, Jay Klievink, Judith Leitner, Petri Pölönen, Helena Hohtari, Khalid Saeed, Tiina Hannunen, Pekka Ellonen, Peter Steinberger, Matti Kankainen, Tero Aittokallio, Mikko A. I. Keränen, Matti Korhonen, Satu Mustjoki

Blood (2020) 135 (9): 597–609.

https://doi.org/10.1182/blood.2019002121

Published: 2020

Includes: Supplemental data

Journal Articles

A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor–positive cells

Marco Ruella, David M. Barrett, Olga Shestova, Jessica Perazzelli, Avery D. Posey, Jr, Seok Jae Hong, Miroslaw Kozlowski, Simon F. Lacey, J. Joseph Melenhorst, Carl H. June, Saar I. Gill

Blood (2020) 135 (7): 505–509.

https://doi.org/10.1182/blood.2019001859

Published: 2020

Includes: Supplemental data

Journal Articles

The one-two punch (of CAR T cells)

Nirali N. Shah

Blood (2020) 135 (5): 303–304.

https://doi.org/10.1182/blood.2019004272

Published: 2020

Journal Articles

Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL

Jing Pan, Shiyu Zuo, Biping Deng, Xiuwen Xu, Chuo Li, Qinlong Zheng, Zhuojun Ling, Weiliang Song, Jinlong Xu, Jiajia Duan, Zelin Wang, Xinjian Yu, Alex H. Chang, Xiaoming Feng, Chunrong Tong

Blood (2020) 135 (5): 387–391.

https://doi.org/10.1182/blood.2019003293

Published: 2020

Includes: Supplemental data

NARROW

CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel

Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy

Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma

Utility of a safety switch to abrogate CD19.CAR T-cell–associated neurotoxicity

Notch signaling promotes disease initiation and progression in murine chronic lymphocytic leukemia

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma

Cryptic insertion of KMT2A , a rare t(9;11) variant

DARTs point the way forward in AML

Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR

Curran KJ, Margossian SP, Kernan NA, et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood. 2019;134(26):2361-2368.

How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies

Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure

Long-term outcomes of Sleeping Beauty–generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas

How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy

Supercharging your CAR

Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity

A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor–positive cells

The one-two punch (of CAR T cells)

Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only